Literature DB >> 8490765

Fluid resuscitation in circulatory shock.

A Imm1, R W Carlson.   

Abstract

Over the past century, the treatment of various forms of circulatory shock has included fluid resuscitation with either crystalloidal or colloidal solutions. Despite decades of investigation, there still is considerable controversy over the beneficial and adverse effects of each fluid type. Most authors agree that the initial resuscitation of any form of shock should be performed with crystalloid solutions. Trauma resuscitation uses crystalloid therapy almost exclusively. Much controversy exists when the shock state involves increased microvascular permeability, such as seen in sepsis, anaphylaxis, and burns. Concerns involve increased permeability pulmonary edema and whether colloid or crystalloid therapy may contribute to its formation. Regardless of fluid type used for resuscitative efforts, it is essential to ensure adequate invasive and noninvasive monitoring to guide therapy. Endpoints to resuscitation should include stabilization of vital signs, adequate urine output, adequate cardiac output, and evidence of supply-independent oxygen consumption. Side effects of aggressive fluid loading are frequent and include intravascular volume overload, pulmonary edema, increased myocardial water content, brain swelling, gastrointestinal ischemia, and massive systemic edema. These complications can best be minimized by careful fluid titration, using physiologic and hemodynamic endpoints.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8490765

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  12 in total

1.  Plasma volume expansion of 5% albumin, 4% gelatin, 6% HES 130/0.4, and normal saline under increased microvascular permeability in the rat.

Authors:  Maris Dubniks; Johan Persson; Per-Olof Grände
Journal:  Intensive Care Med       Date:  2006-11-21       Impact factor: 17.440

Review 2.  Colloid volume expanders. Problems, pitfalls and possibilities.

Authors:  J S Roberts; S L Bratton
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 3.  Exploding the albumin myth.

Authors:  M M Tjoeng; A K Bartelink; L G Thijs
Journal:  Pharm World Sci       Date:  1999-02

4.  Volume expansion of albumin, gelatin, hydroxyethyl starch, saline and erythrocytes after haemorrhage in the rat.

Authors:  Johan Persson; Per-Olof Grände
Journal:  Intensive Care Med       Date:  2004-12-18       Impact factor: 17.440

5.  Protective roles of hydroxyethyl starch 130/0.4 in intestinal inflammatory response and oxidative stress after hemorrhagic shock and resuscitation in rats.

Authors:  Pengfei Wang; Yousheng Li; Jieshou Li
Journal:  Inflammation       Date:  2009-04       Impact factor: 4.092

6.  Investigation of the cause of readmission to the intensive care unit for patients with lung edema or atelectasis.

Authors:  Yoshinori Matsuoka; Akinori Zaitsu; Makoto Hashizume
Journal:  Yonsei Med J       Date:  2008-06-30       Impact factor: 2.759

Review 7.  Planned reoperation for severe trauma.

Authors:  A Hirshberg; K L Mattox
Journal:  Ann Surg       Date:  1995-07       Impact factor: 12.969

8.  Effect of blood pressure on plasma volume loss in the rat under increased permeability.

Authors:  Maris Dubniks; Johan Persson; Per-Olof Grände
Journal:  Intensive Care Med       Date:  2007-07-11       Impact factor: 17.440

9.  Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study.

Authors:  Tim Philipp Simon; Tobias Schuerholz; Lars Hüter; Michael Sasse; Florian Heyder; Wolfgang Pfister; Gernot Marx
Journal:  Crit Care       Date:  2012-01-25       Impact factor: 9.097

10.  Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model.

Authors:  Lars Hüter; Tim-Philipp Simon; Lenard Weinmann; Tobias Schuerholz; Konrad Reinhart; Gunter Wolf; Kerstin Ute Amann; Gernot Marx
Journal:  Crit Care       Date:  2009-02-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.